Eisai, BMS to develop antibody-drug conjugate for solid tumors

By The Science Advisory Board staff writers

June 18, 2021 -- Eisai and Bristol Myers Squibb (BMS) have entered a global strategic collaboration to develop and commercialize MORAb-202, an antibody-drug conjugate.

MORAb-202 is Eisai's first antibody drug conjugate and combines the company's in-house-developed antifolate receptor alpha antibody with its anticancer agent eribulin, using an enzyme-cleavable linker. The payload eribulin, known as Halaven, is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action.

The two companies will jointly develop and commercialize MORAb-202 in the following areas: Japan, China, countries in the Asia-Pacific region, the U.S., Canada, Europe (including the European Union and the U.K.), and Russia.

BMS will be responsible for developing and commercializing the drug in regions outside of the collaboration territories. Eisai will remain responsible for the manufacturing and supply of MORAb-202 globally.

Under the collaboration, BMS will pay $650 million to Eisai, including $200 million as payment toward Eisai research and development expenses. Eisai is also entitled to receive up to $2.5 billion in potential future development, regulatory, and commercial milestones.

The companies will share profits, research and development, and commercialization costs in the collaboration territories. BMS will also pay Eisai a royalty on sales outside of the collaboration territories.

Copyright © 2021 scienceboard.net

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.